- Report
- April 2024
- 150 Pages
Global
From €5640EUR$5,950USD£4,711GBP
- Report
- March 2025
- 200 Pages
Global
From €4256EUR$4,490USD£3,555GBP
- Drug Pipelines
- July 2024
- 150 Pages
Global
From €3554EUR$3,750USD£2,969GBP
- Report
- May 2024
- 200 Pages
Global
From €3933EUR$4,150USD£3,286GBP
- Report
- July 2022
Global
From €4265EUR$4,500USD£3,563GBP
- Report
- March 2024
- 238 Pages
Global
From €7535EUR$7,950USD£6,295GBP
- Clinical Trials
- April 2024
- 60 Pages
Global
From €1896EUR$2,000USD£1,584GBP
- Drug Pipelines
- April 2024
- 70 Pages
Global
From €1422EUR$1,500USD£1,188GBP
- Clinical Trials
- April 2024
- 50 Pages
Global
From €1422EUR$1,500USD£1,188GBP
- Clinical Trials
- April 2024
- 60 Pages
Global
From €1422EUR$1,500USD£1,188GBP
- Clinical Trials
- April 2024
- 40 Pages
Global
From €1185EUR$1,250USD£990GBP
- Report
- March 2024
- 74 Pages
Global
From €3500EUR$3,956USD£3,026GBP
- Report
- November 2024
- 78 Pages
Global
From €3500EUR$3,956USD£3,026GBP
- Report
- September 2022
- 41 Pages
Global
From €1896EUR$2,000USD£1,584GBP
- Report
- July 2022
- 173 Pages
Global
From €1896EUR$2,000USD£1,584GBP

Sulbactam is an antibiotic drug used in combination with other antibiotics to treat a variety of bacterial infections. It is a beta-lactamase inhibitor, meaning it blocks the action of enzymes that can break down other antibiotics, allowing them to remain active and effective against bacteria. Sulbactam is commonly used in combination with ampicillin to treat infections caused by susceptible bacteria, such as urinary tract infections, skin and soft tissue infections, and intra-abdominal infections. It is also used to treat some types of meningitis and endocarditis.
Sulbactam is a key component of many antibiotics used to treat infectious diseases, and is an important part of the global effort to combat antibiotic resistance. It is used in combination with other antibiotics to increase the effectiveness of treatment and reduce the risk of antibiotic resistance.
Some companies in the Sulbactam market include Merck & Co., Inc., Pfizer, Inc., GlaxoSmithKline plc, Sanofi, and AstraZeneca plc. Show Less Read more